Food Aversion during Cancer Treatment: A Systematic Review

References

• Hinkelmann JV, Possa LO, de Oliveira CA, Faria BS, Hermsdorff HHM, Rosa COB. Food preferences and aversions of patients undergoing chemotherapy, radiotherapy and/or hematopoietic stem cell transplantation. Clin Nutr ESPEN. 2021;44:331–6. doi:10.1016/j.clnesp.2021.05.023
   PubMed Web of Science ®Google Scholar
• Mattes RD, Arnold C, Boraas M. Learned food aversions among cancer chemotherapy patients incidence, nature, and clinical implications. Cancer. 1987;60(10):2576–80. doi:10.1002/1097-0142(19871115)60:10<2576::AID-CNCR2820601038>3.0.CO;2-5
   PubMed Web of Science ®Google Scholar
• Andresen GV, Birch LL, Johnson PA. The scapegoat effect on food aversions after chemotherapy. Cancer. 1990;66(7):1649–53. doi:10.1002/1097-0142(19901001)66:7<1649::AID-CNCR2820660733>3.0.CO;2-7
   PubMed Web of Science ®Google Scholar
• Scalera G. Effects of conditioned food aversions on nutritional behavior in humans. Nutr Neurosci. 2002;5(3):159–88. doi:10.1080/10284150290013059
   PubMed Web of Science ®Google Scholar
• Boltong A, Keast R. The influence of chemotherapy on taste perception and food hedonics: a systematic review. Cancer Treat Rev. 2012;38(2):152–63. doi:10.1016/j.ctrv.2011.04.008
   PubMed Web of Science ®Google Scholar
• Ellender G, Coveney J. Flavor alterations in cancer treatment: Extrinsic factors as a means of augmentation. Clin Nutr ESPEN. 2021;43:76–89. doi:10.1016/j.clnesp.2021.02.016
   PubMed Web of Science ®Google Scholar
• Nolden AA, Hwang LD, Boltong A, Reed DR. Chemosensory changes from cancer treatment and their effects on patients’ food behavior: a scoping review. Nutrients. 2019;11(10):2285. doi:10.3390/nu11102285
   PubMed Web of Science ®Google Scholar
• Padilla GV. Psychological aspects of nutrition and cancer. Surg Clin North Am. 1986;66(6):1121–35. doi:10.1016/S0039-6109(16)44078-8
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:1–8.
   Google Scholar
• Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan — a web and mobile app for. Syst Rev. 2016;5(1):1–10. doi:10.1186/s13643-016-0384-4
   PubMedGoogle Scholar
• Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MK, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomized trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
   PubMed Web of Science ®Google Scholar
• Lockwood C, Munn Z, Porritt K. Qualitative research synthesis: methodological guidance for systematic reviewers utilizing meta-aggregation. Int J Evid Based Healthc. 2015;13(3):179–87. doi:10.1097/XEB.0000000000000062
   PubMed Web of Science ®Google Scholar
• Anderson RJ, Bloch S, Armstrong M, Stone PC, Low JT. Communication between healthcare professionals and relatives of patients approaching the end-of-life: a systematic review of qualitative evidence. Palliat Med. 2019;33(8):926–41. doi:10.1177/0269216319852007
   PubMed Web of Science ®Google Scholar
• Jacobsen PB, Bovbjerg DH, Schwartz MD, Andrykowski MA, Futterman AD, Gilewski T, Norton L, Redd WH. Formation of food aversions in cancer patients receiving repeated infusions of chemotherapy. Behav Res Thu. 1993;31(8):739–48. doi:10.1016/0005-7967(93)90004-E
   PubMed Web of Science ®Google Scholar
• Schwartz MD, Jacobsen PB, Bovbjerg DH. Role of nausea in the development of aversions to a beverage paired with chemotherapy treatment in cancer patients. Physiol Behav. 1996;59(4–5):659–63. doi:10.1016/0031-9384(95)02096-9
   PubMed Web of Science ®Google Scholar
• Andrykowski MA, Otis ML. Development of learned food aversions in humans: investigation in a “natural laboratory” of cancer chemotherapy. Appetite. 1990;14(2):145–58. doi:10.1016/0195-6663(90)90016-2
   PubMed Web of Science ®Google Scholar
• Smith JL, Malinauskas BM, Garner KJ, Barber-Heidal K. Factors contributing to weight loss,nutrition-related concerns and advice received by adults undergoing cancer treatment. Adv Med Sci. 2008;53(2):198–204.
   PubMed Web of Science ®Google Scholar
• Mattes RD, Curran WJ, Jr, Alavi J, Powlis W, Whittington R. Clinical implications of learned food aversions in patients with cancer treated with chemotherapy or radiation therapy. Cancer. 1992;70(1):192–200. doi:10.1002/1097-0142(19920701)70:1<192::AID-CNCR2820700130>3.0.CO;2-G
   PubMed Web of Science ®Google Scholar
• Guerdoux-Ninot E, Kilgour RD, Janiszewski C, Jarlier M, Meuric J, Poirée B, Buzzo S, Ninot G, Courraud J, Wismer W, et al. Meal context and food preferences in cancer patients: results from a French self‐report survey. Springerplus. 2016;5(1):810. doi:10.1186/s40064-016-2538-1
   PubMedGoogle Scholar
• Mattes RD, Curran WJ, Jr, Powlis W, Whittington R. A descriptive study of learned food aversions in radiotherapy patients. Physiol Behav. 1991;50(6):1103–9. doi:10.1016/0031-9384(91)90568-9
   PubMed Web of Science ®Google Scholar
• Mattes RD. Prevention of food aversions in cancer patients during treatment. Nutr Cancer. 1994;21(1):13–24. doi:10.1080/01635589409514300
   PubMed Web of Science ®Google Scholar
• Mattes RD, Arnold C, Boraas M. Management of learned food aversions in cancer patients receiving chemotherapy. Cancer Treat Rep. 1987;71(11):1071–8.
   PubMedGoogle Scholar
• de Vries YC, Helmich E, Karsten MD, Boesveldt S, Winkels RM, Laarhoven WHM. The impact of chemosensory and food-related changes in patients with advanced oesophagogastric cancer treated with capecitabine and oxaliplatin: a qualitative study. Support Care Cancer. 2016;24(7):3119–26. doi:10.1007/s00520-016-3128-z
   PubMed Web of Science ®Google Scholar
• Prockmann S, Ruschel Freitas AH, Gonçalves Ferreira M, Kunradi Vieira FG, Kuerten de Salles R. Evaluation of diet acceptance by patients with haematological cancer during chemotherapeutic treatment. Nutr Hosp. 2015;32(2):779–84. doi:10.3305/nh.2015.32.2.8958
   PubMed Web of Science ®Google Scholar
• Coa KI, Epstein JB, Ettinger D, Jatoi A, McManus K, Platek ME, Wendy P, Stewart M, Teknos TN, Moskowitz B. The impact of cancer treatment on the diets and food preferences of patients receiving outpatient treatment. Nutr Cancer. 2015;67(2):339–53. doi:10.1080/01635581.2015.990577
   PubMed Web of Science ®Google Scholar
• Fisberg RM, Marchioni DML, Colucci ACA. Avaliação do consumo alimentar e da ingestão de nutrientes na prática clínica. Arq Bras Endocrinol Metabol. 2009;53(5):617–24. doi:10.1590/s0004-27302009000500014
   PubMedGoogle Scholar
• Plata-Salamán CR. Central nervous system mechanisms contributing to the cachexia – anorexia syndrome. Nutrition. 2000;16(10):1009–12. doi:10.1016/S0899-9007(00)00413-5
   PubMed Web of Science ®Google Scholar
• Hariyanto TI, Kurniawan A. Appetite problem in cancer patients: pathophysiology, diagnosis, and treatment. Cancer Treat Res Commun. 2021;27:100336. doi:10.1016/j.ctarc.2021.100336
   PubMedGoogle Scholar
• Malla J, Zahra A, Venugopal S, Selvamani TY, Shoukrie SI, Selvaraj R, Dhanoa RK, Hamouda RK, Mostafa J. What role do inflammatory cytokines play in cancer cachexia? Cureus. 2022;14(7):e26798. doi:10.7759/cureus.26798
   PubMed Web of Science ®Google Scholar
• Laird BJ, McMillan D, Skipworth RJE, Fallon MT, Paval DR, McNeish I, Gallagher IJ. The emerging role of interleukin 1β (IL-1β) in cancer cachexia. Inflammation. 2021;44(4):1223–8. doi:10.1007/s10753-021-01429-8
   PubMed Web of Science ®Google Scholar
• Mastorakos G, Zapanti E. The hypothalamic-pituitary-adrenal axis in the neuroendocrine regulation of food intake and obesity: the role of corticotropin releasing hormone. Nutr Neurosci. 2004;7(5-6):271–80. doi:10.1080/10284150400020516
   PubMed Web of Science ®Google Scholar
• Tsai VWW, Husaini Y, Sainsbury A, Brown DA, Breit SN. The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 2018;28(3):353–68. doi:10.1016/j.cmet.2018.07.018
   PubMed Web of Science ®Google Scholar
• Tsung-Chieh L, Hsiao M. Ghrelin and cancer progression. Biochim Biophys Acta Rev Cancer. 2017;1868(1):51–7. doi:10.1016/j.bbcan.2017.02.002
   PubMed Web of Science ®Google Scholar
• Ahmed DS, Isnard S, Lin J, Routy B, Routy JP. GDF15/GFRAL pathway as a metabolic signature for cachexia in patients with cancer. J Cancer. 2021;12(4):1125–32. doi:10.7150/jca.50376
   PubMed Web of Science ®Google Scholar
• Schéle E, Cook C, Le May M, Bake T, Luckman SM, Dickson SL. Central administration of ghrelin induces conditioned avoidance in rodents. Eur Neuropsychopharmacol. 2017;27(8):809–15. doi:10.1016/j.euroneuro.2017.05.001
   PubMed Web of Science ®Google Scholar
• Kotta AS, Kelling AS, Corleto KA, Sun Y, Giles ED. Ghrelin and cancer: examining the roles of the ghrelin axis in tumor growth and progression. Biomolecules. 2022;12(4):483. doi:10.3390/biom12040483
   PubMed Web of Science ®Google Scholar
• Bernstein IL, Treneer CM, Goehler LE, Murowchick E. Tumor growth in rats: conditioned suppression of food intake and preference. Behav Neurosci. 1985;99(5):818–30. doi:10.1037/0735-7044.99.5.818
   PubMed Web of Science ®Google Scholar
• Bernstein IL. Neutral mediation of food aversions and anorexia induced by tumor necrosis factor and tumors. Neurosci Biobehav Rev. 1996;20(1):177–81. doi:10.1016/0149-7634(95)00046-H
   PubMed Web of Science ®Google Scholar
• Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP, Erickson N, Laviano A, Lisanti MP, Lobo DN, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr. 2017;36(5):1187–96. doi:10.1016/j.clnu.2017.06.017
   PubMed Web of Science ®Google Scholar
• Marks DL, Ling N, Cone RD. Role of the central melanocortin system in cachexia. Cancer Res. 2001 Feb 15;61(4):1432–8.
   PubMed Web of Science ®Google Scholar
• Olson B, Diba P, Korzun T, Marks DL. Neural mechanisms of cancer cachexia. Cancers (Basel). 2021;13(16):3990. doi:10.3390/cancers13163990
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95. doi:10.1016/S1470-2045(10)70218-7
   PubMed Web of Science ®Google Scholar
• Poulia KA, Sarantis P, Antoniadou D, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Pancreatic cancer and cachexia-metabolic mechanisms and novel insights. Nutrients. 2020;12(6):1543. doi:10.3390/nu12061543
   PubMed Web of Science ®Google Scholar